Description

Teleflex: What’s Powering Its Explosive Vascular Intervention Expansion?

Teleflex Inc. released its third-quarter 2025 results amidst its ongoing corporate transformation strategy. The company continues to progress with its separation into two independent entities, RemainCo and NewCo, aiming for improved focus and enhanced shareholder value. The management is prioritizing a potential sale of NewCo, reflecting the healthy buyer interest and advanced stage in the process. The company’s third-quarter revenues reached $913 million, marking a 19.4% year-over-year increase on a GAAP basis. Adjusted revenues stood at $892.9 million, showing a 16.8% increase year-over-year, excluding the impact of Italian payback measures. This strong revenue growth was driven by contributions from the acquired Vascular Interventions business, although organic growth excluding acquisitions was only 2.3%. Regionally, the Americas reported $555.9 million in revenue, with a 7.5% increase driven mainly by the Vascular Intervention business. EMEA revenues rose 34.4% to $214.1 million, while Asia reported a 25.3% increase to $122.